{"commentary":{"count":31,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":13,"youtube":9,"podcast":9},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00626990\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CATNON","nct_id":"NCT00626990","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=catnon-nct00626990. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"CATNON","arms":[{"description":"radiation therapy alone","label":"Radiotherapy (RT) alone","type":"ACTIVE_COMPARATOR"},{"description":"Radiotherapy and concurrent temozolomide chemotherapy","label":"RT & Concurrent CT","type":"ACTIVE_COMPARATOR"},{"description":"Radiotherapy plus adjuvant temozolomide chemotherapy","label":"RT + Adjuvant CT","type":"ACTIVE_COMPARATOR"},{"description":"Radiotherapy and concurrent chemotherapy plus adjuvant temozolomide chemotherapy","label":"RT & Concurrent CT + adjuvant CT","type":"ACTIVE_COMPARATOR"}],"collaborators":["NCIC Clinical Trials Group","Radiation Therapy Oncology Group","Medical Research Council","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2029-12","type":"ESTIMATED"},"conditions":["Brain and Central Nervous System Tumors"],"enrollment":{"count":751,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"temozolomide","type":"DRUG"},{"name":"DNA methylation analysis","type":"GENETIC"},{"name":"laboratory biomarker analysis","type":"OTHER"},{"name":"adjuvant therapy","type":"PROCEDURE"},{"name":"quality-of-life assessment","type":"PROCEDURE"},{"name":"radiation therapy","type":"RADIATION"}],"last_update":"2023-09-11","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","official_title":"Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2018-09-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival as Measured From the Day of Randomization","timeFrame":"from date from enrollment till the date of death (time till death is up to 10.9 years after patient enrollment in the study)"}],"references":[{"citation":"van den Bent MJ, Ghisai SA, Wick W, Sanson M, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Tabouret E, Gill S, Griffin M, Taal W, Ruda R, Weller M, McBain C, Reijneveld JC, Enting RH, Tran S, Lesimple T, Kocher M, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Hoogstrate Y, Nuyens S, Golfinopoulos V, Tesileanu CMS, Gorlia T, French P, Baumert BG. Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial. Lancet Oncol. 2026 Jan;27(1):45-56. doi: 10.1016/S1470-2045(25)00614-X.","pmid":"41449147","type":"DERIVED"},{"citation":"Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Ruda R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clin Cancer Res. 2022 Jun 13;28(12):2527-2535. doi: 10.1158/1078-0432.CCR-21-4283.","pmid":"35275197","type":"DERIVED"},{"citation":"van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Ruda R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14.","pmid":"34000245","type":"DERIVED"},{"citation":"van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Ruda R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8.","pmid":"28801186","type":"DERIVED"}],"start_date":{"date":"2007-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)","url":"https://clinicaltrials.gov/study/NCT00626990"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/catnon-nct00626990"}